INFORMATION FOR PATIENTS

UNDERSTANDING THE DEFINITIVE STUDY

Receiving a diagnosis of breast cancer can feel overwhelming, and making treatment decisions is not always easy. The DEFINITIVE study was created to help make this journey clearer and more personalized for people with early-stage HER2-positive breast cancer.

watch patient stories considering participation

This European research study, funded by the European Commission (Project Number101136953), aims to show that using a personalized diagnostic test called HER2DX^® canhelp doctors choose treatments that maintain excellent outcomes while improving quality of life. In other words, the goal is to ensure that patients receive the treatment they need—no more and no less—without compromising eﬀectiveness or survival.

The study brings together 18 expert partners from 7 European countries, includingdoctors, researchers, and patient-focused organizations, all working together to improvecare for people affected by breast cancer.

expert partners

European countries

funded by the European Commission,
Project Number 101136953

PATIENTS

PATIENT VOICES

People living with early-stage HER2-positive breast cancer share, in their own language, what it means to take part in research and to receive more personalized care.

These testimonials reflect personal experiences and are not medical advice. Participants have given their consent to share their stories. Talk to your oncologist about what is right for you.

CONTACT THE STUDY TEAM

SPANISH

FRENCH

ITALIAN

GERMAN

THE TEST

WHAT IS HER2DX^®?

A diagnostic test developed by REVEAL GENOMICS^® that helps your doctor understand how your cancer may behave, and how likely it is to respond to treatment.

01

Your tumor sample

The test uses tissue fromthe biopsy taken at diagnosis.

02

27 genes + clinical details

Gene activity is combined with tumour size andwhether lymph nodes are aﬀected.

03

AI-based analysis

An algorithm turns this information into scores.

04

A clearer plan with your doctor

Your oncologist uses the result to help choose the right treatment for you.

WHY IT MATTERS

HOW COULD THE STUDY HELP PATIENTS

Every patient is diﬀerent, and breast cancer does not aﬀect everyone in the same way. The test is designed to bring greater clarity and confidence to treatment planning.
The DEFINITIVE study will help confirm how useful this test is in everyday clinical practice and whether it can improve patients’ experiences and well-being.

More personalised treatment

Some patients may receive less intensive treatment with fewer side eﬀects. Those at higher risk may receive more intensive care for the best protection.

Better decisions before surgery

The test helps predict whether the tumour is likely to fully respond to treatment givenbefore surgery,

Clearer planning after surgery

It may help decide whether further treatment is needed and for how long, avoiding unnecessary treatment for some patients.

TAKING PART

CONSIDERING PARTICIPATION

Taking part in a clinical study is a personal decision. Participation in the DEFINITIVE study is completely voluntary, and choosing not to take part will not aﬀect your medical care in anyway.
If you would like to learn more or explore whether this study might be right for you, we encourage you to:

Speak with your oncologist

Contact the study team at

info@thedefinitivetrial.eu

We are grateful to every patient who considers contributing to research. Your participation helps advance knowledge and improve care for future patients.